The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants

Last updated: May 19, 2025
Sponsor: Bharat Biotech International Limited
Overall Status: Active - Not Recruiting

Phase

3

Condition

N/A

Treatment

Placebo

ROTAVAC 5D

Clinical Study ID

NCT06200844
BBIL/Rotavac 5D-CHILE /2022
  • Ages 6-8
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy,Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants aged 6-8 weeks.

A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. At least one parent(s) or legally acceptable representative's consent forparticipation and are able to understand study procedures

  2. Subjects aged 6 to 8 weeks at recruitment

  3. No plans to move in the next 12 months

Exclusion

Exclusion Criteria:

  1. Administration of rotavirus vaccine in the past

  2. Presence of any illness requiring hospital referral (temporary exclusion)

  3. Known case of immunodeficiency disease, known HIV positive

  4. Known case of chronic gastroenteritis disease, chronic pulmonary disease, chronicrenal disease, congenital heart disease

  5. Any other conditions which in the judgment of the investigator warrant exclusion (e.g. no exclusion criteria but seems 'ill', investigators suspects neglect)

  6. Diarrhea on the day of enrollment (temporary exclusion)

  7. A known sensitivity or allergy to any components of the study vaccines.

  8. Major congenital or genetic defect.

  9. Has received any immunoglobulin therapy and/or blood products since birth.

  10. History of chronic administration (defined as more than 14 days) ofimmunosuppressants including corticosteroids. Infants on inhaled or topical steroidsmay be permitted to participate in the study, at the discretion of the principalinvestigator.

Study Design

Total Participants: 5800
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
July 07, 2023
Estimated Completion Date:
July 31, 2026

Study Description

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy, Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants aged 6-8 weeks.

A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response. Inclusion At least one parent(s) or legally acceptable representative's consent for participation and are able to understand study procedures Subjects aged 6 to 8 weeks at recruitment No plans to move in the next 12 months Exclusion Administration of rotavirus vaccine in the past Presence of any illness requiring hospital referral (temporary exclusion) Known case of immunodeficiency disease, known HIV positive Known case of chronic gastroenteritis disease, chronic pulmonary disease, chronic renal disease, congenital heart disease Any other conditions which in the judgment of the investigator warrant exclusion (e.g. no exclusion criteria but seems 'ill', investigators suspects neglect) Diarrhea on the day of enrollment (temporary exclusion) A known sensitivity or allergy to any components of the study vaccines. Major congenital or genetic defect. Has received any immunoglobulin therapy and/or blood products since birth. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study, at the discretion of the principal investigator. Blood samples: In the "Immunogenicity Subset", 3 ml blood specimens will be collected at baseline and 28 (+) 5 days after the third dose of the Test Article/placebo to assess the anti rotavirus IgA antibody titer. Stool Specimens: The study team will attempt to collect a stool specimen for every GE episode, preferably within the first 2 days after episode onset. The stool specimen may be collected up to 7 days after the last day of diarrhea. The stool specimens will be sent to the laboratory. If the episode is a suspected intussusception or vaccine associated gastroenteritis that has occurred within four weeks after each dose of the Test Article/placebo, the specimen will be sent to the laboratory immediately for rotavirus testing and typing. For all ELISA RV positive samples, an aliquot of the stool specimen will be assessed for 20 enteropathogens by multiplex-PCR panel and to identify the genotype of the virus.

Connect with a study center

  • Vacunatorio Mediped

    Antofagasta, 1240000
    Chile

    Site Not Available

  • Vacunatorio Kinewen

    Concepción, 4070118
    Chile

    Site Not Available

  • CESFAM Dr. Alejandro Gutierrez

    Coyhaique, 5950000
    Chile

    Site Not Available

  • Hospital de Puerto Montt

    Los Lagos, 5480000
    Chile

    Site Not Available

  • Hospital Base Osorno ,Av. Guillermo Buhler 1765

    Osorno, 5290000
    Chile

    Site Not Available

  • CESFAM Puerto Aysen

    Puerto Aysén, 6000594
    Chile

    Site Not Available

  • Centro de Investigación vacunas Hospital de Puerto Montt

    Puerto Montt, 5480000
    Chile

    Site Not Available

  • CESFAM Colina

    Santiago, 9350079
    Chile

    Site Not Available

  • CESFAM Esmeralda

    Santiago, 9340000
    Chile

    Site Not Available

  • CESFAM Lo Barnechea

    Santiago,
    Chile

    Site Not Available

  • CESFAM Santa julia

    Santiago, 5480000
    Chile

    Active - Recruiting

  • Centro de Salud Familiar CESFAM Rosita Renard

    Santiago, 7500539
    Chile

    Site Not Available

  • Consultorio Dr. Alejandro del Rio

    Santiago, 8210269
    Chile

    Site Not Available

  • Hospital Exequiel Gónzalez Cortés

    Santiago,
    Chile

    Site Not Available

  • Hospital de Carabineros

    Santiago, 7770201
    Chile

    Site Not Available

  • Hospital de ninos Roberto del Rio

    Santiago, 8380418
    Chile

    Site Not Available

  • CESFAM Jean y Marie Thierry de Valparaíso

    Valparaíso, 2340319
    Chile

    Site Not Available

  • Hospital Gustavo Fricke

    Viña Del Mar, 2520000
    Chile

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.